References
- Sánchez-de la Rosa R, Sabater E, Casado MA, et al. Cost-effectiveness analysis of disease modifying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. J Med Econ 2012;15(3):424-33
- Bell C. The pursuit of transparency and quality improvement in cost-effectiveness analysis-A case study in Disease-Modifying Drugs for the treatment of Multiple Sclerosis. J Manag Care Pharm 2011;17:46-7
- Bell C, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61